Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Dueling Commentaries In JAMA Revisit US FDA Approval Of Abiomed’s Impella

This article was originally published in Clinica

Executive Summary

Is the US FDA’s 515 Program Initiative for so-called “pre-amendment” technologies, leading to approvals of high-risk devices, based on flawed evidence? This question is addressed by two expert commentaries, posted online by JAMA Cardiology on March 9, that review the US FDA’s 2015 approval of Abiomed’s Impella 2.5 percutaneous ventricular assist device under the 515 Program Initiative.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register